Prokaryotic rRNA-mRNA interactions are involved in all translation steps and shape bacterial transcripts

Elitzur, Shir Bahiri; Cohen-Kupiec, Rachel; Yacobi, Dana; Fine, Larissa; Apt, Boaz; Diament, Alon; Tuller, Tamir

doi:10.1080/15476286.2021.1978767

Cited by 6 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The protamine-mRNA complexes can also function as adjuvant, activating TLR7/8 to elicit Th-1 type immune response [594]. However, protamine-mRNA complexes alone showed suboptimal translation efficiency, which might be due to an excessively tight interaction between protamine and mRNA [595]. This concern has been solved by a two-compartment formulation, RNActive ® , developed by CureVac AG [596].…”

Section: Peptide-based Mrna Delivery Systemmentioning

confidence: 99%

“…The researchers combined protamine-mRNA complexes (50%) with naked antigen-coding mRNA(s) (50%). The protamine complexes act only as adjuvant, while the nucleoside modified mRNA acts as antigen producer [595]. RNActive ® encapsulating TAAsencoding mRNAs are currently being evaluated in several phase I/II clinical trials treating multiple solid tumors [116].…”

Section: Peptide-based Mrna Delivery Systemmentioning

confidence: 99%

See 1 more Smart Citation

The use of RNA-based treatments in the field of cancer immunotherapy

Chehelgerdi

2023

Mol Cancer

View full text Add to dashboard Cite

Over the past several decades, mRNA vaccines have evolved from a theoretical concept to a clinical reality. These vaccines offer several advantages over traditional vaccine techniques, including their high potency, rapid development, low-cost manufacturing, and safe administration. However, until recently, concerns over the instability and inefficient distribution of mRNA in vivo have limited their utility. Fortunately, recent technological advancements have mostly resolved these concerns, resulting in the development of numerous mRNA vaccination platforms for infectious diseases and various types of cancer. These platforms have shown promising outcomes in both animal models and humans. This study highlights the potential of mRNA vaccines as a promising alternative approach to conventional vaccine techniques and cancer treatment. This review article aims to provide a thorough and detailed examination of mRNA vaccines, including their mechanisms of action and potential applications in cancer immunotherapy. Additionally, the article will analyze the current state of mRNA vaccine technology and highlight future directions for the development and implementation of this promising vaccine platform as a mainstream therapeutic option. The review will also discuss potential challenges and limitations of mRNA vaccines, such as their stability and in vivo distribution, and suggest ways to overcome these issues. By providing a comprehensive overview and critical analysis of mRNA vaccines, this review aims to contribute to the advancement of this innovative approach to cancer treatment.

show abstract

Section: Peptide-based Mrna Delivery Systemmentioning

confidence: 99%

Section: Peptide-based Mrna Delivery Systemmentioning

confidence: 99%